Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464801 | 0.86 | GNAI3 (0.49) | GNAI3GNAI1L3MBTL1GNAO1MEN1 | |
| SCHEMBL5244391 | 0.80 | GNAI3 (0.62) | GNAI3GNAI1L3MBTL1GNAO1MEN1 | |
| SCHEMBL5243155 | 0.80 | GNAI3 (0.72) | GNAI3GNAI1L3MBTL1GNAO1MEN1 | |
| SCHEMBL20466537 | 0.80 | HRH3 (0.56) | HRH3GNAI3GNAI1L3MBTL1GNAO1 | |
| Ammonia Solution, Strong SCHEMBL3990591 | 0.80 | GNAI3 (0.55) | GNAI3GNAI1L3MBTL1GNAO1MEN1 | |
| SCHEMBL24368020 | 0.78 | HRH3 (0.57) | HRH3GNAI3GNAI1L3MBTL1MEN1 | |
| SCHEMBL16221897 | 0.77 | GNAI3 (0.53) | GNAI3GNAI1L3MBTL1GNAO1MEN1 | |
| SCHEMBL25694557 | 0.77 | GNAI3 (0.53) | GNAI3GNAI1L3MBTL1GNAO1MEN1 | |
| SCHEMBL23561249 | 0.77 | HRH3 (0.51) | HRH3MEN1KMT2ATDP1NPC1 | |
| SCHEMBL14540477 | 0.77 | ATM (0.59) | GNAI3GNAI1L3MBTL1GNAO1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | HRH3 4821/4885GNAI3 1942/4885GNAI1 2223/4885 |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | HRH3 4821/4885GNAI3 1942/4885GNAI1 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.